Novoste Corporation, based in Atlanta, Georgia, develops advanced medical treatments for coronary and vascular diseases and is the worldwide leader in vascular brachytherapy - radiation therapy delivered inside a blood vessel to prevent it from re-closing (restenosis) following balloon angioplasty and other catheter-based interventional procedures. The NovosteT Beta-CathT System is commercially available in the United States, as well as in the European Union and several other countries.

The Beta-CathT System is primarily used to treat patients suffering from in-stent restenosis, a condition in which coronary stents become blocked with new tissue growth.